< 回列表
Rachel Wen-Juei Jeng
- Professor of Medicine, Chang Gung University
- Professor, Chang Gung Memorial Hospital, Linkou branch, Taiwan
- Deputy director, Clinical Trial Center, Chang Gung Memorial Hospital, Linkou branch, Taiwan
- Deputy Secretary-general, Taiwan Association for the Study of Liver (EALA activity, Finance)
學歷 / 訓練
2022, PhD., Graduate School of Institute of Clinical Medicine, National Yang-Ming University, Taiwan
2005, M.D., College of Medicine, National Yang-Ming University, Taiwan
專業與研究經歷
2024 - Present, Professor, College of Medicine, Chang Gung University
2022 - Present, Professor, Chang Gung Memorial Hospital
2020 - 2024, Associate Professor, College of Medicine, Chang Gung University
2019 - 2022, Associate Professor, Chang Gung Memorial Hospital
2016 - 2020, Associate Professor, College of Medicine, Chang Gung University
2015 - 2019, Associate Professor, Chang Gung Memorial Hospital
獲獎與榮譽
2023
Young investigator award, Chang Gung University
2022
Research award--Liver, the 1st place, TDDW
2022
Young investigator award, Chang Gung University
2022
Ta-You Wu Memorial Award
2022
The outstanding abstract award, APASL-STC
2022
The outstanding presentation award, APASL-STC
重要出版品
- Refining HCC Risk Prediction in Non-ACLD Chronic Hepatitis Patients After Antiviral Therapy: Insights from a Multicenter Study. Poster presentation EASL 2025 (TOP poster)
- Accelerated HBsAg reduction rate and increased proportion of HBsAg <100 IU/mL through repeated finite Nuc therapy in HBeAg-negative chronic hepatitis B patients. Poster presentation EASL 2025 (TOP poster), TDDW 2025 oral presentation
- Higher Sustained Response rate and Partial cure in NUC Experienced Pegylated Interferon-Treated Patients Compared to NUC Naïve Pegylated Interferon Monotherapy Patients. Poster presentation AASLD 2024
- Hepatitis B virus genotype and some baseline characteristics, but not race, affect HBsAg kinetics during nucleos(t)ide analogue therapy. Poster presentation EASL 2024
- Persistence of fatty liver index (FLI) ≥ 20 as a predictor for hepatocellular carcinoma (HCC) development in non-HBV/non-HCV infected population. Poster presentation EASL 2024
- A fatty liver index greater than 20 increased the risk of hepatocellular carcinoma among subjects with non-viral hepatitis in an HBV endemic region. Poster presentation APASL-STC 2024